Accession Number : AD1005097

Title :   EF5 PET of Tumor Hypoxia: A Predictive Imaging Biomarker of Response to Stereotactic Ablative Radiotherapy (SABR) for Early Lung Cancer

Descriptive Note : Technical Report,15 Aug 2014,14 Aug 2015

Corporate Author : Stanford University Stanford United States

Personal Author(s) : Loo,Billy Jr W

Full Text :

Report Date : 01 Sep 2015

Pagination or Media Count : 9

Abstract : Stereotactic ablative radiotherapy (SABR) has become a new standard of care for early stage lung cancer in patients who arenot candidates for surgery because of excessive surgical risk, and will be an important treatment option for a growing segmentof patients with lung cancer. This is particularly true as lung cancer screening efforts are expected to diagnose a greaterproportion of lung cancers at earlier stages, yet the aging of the population will lead to a greater proportion of patients havingcomorbidities that increase surgical risk. Tumor hypoxia is a major known mechanism of radiation resistance and is especiallyexpected to affect very short courses of radiation as in SABR. Imaging using a third generation hypoxia PET agent, 18F-EF5, isa promising approach for noninvasive hypoxia measurement that needs to be validated in the clinical setting.Our objectives are (1) to understand the prevalence of hypoxia detectable by imaging in early stage NSCLC; (2) to validate18F-EF5 PET as an indicator of tumor oxygenation status in this patient population; and (3) to evaluate 18F-EF5 PET as aprognostic imaging biomarker for local primary tumor control after SABR.

Descriptors :   radiotherapy , lung cancer , hypoxia , NEOPLASMS , patients , MEDICAL SCREENING

Distribution Statement : APPROVED FOR PUBLIC RELEASE